Australian officials mum on details of drug stockpile purchase

06/3/2004 | Australian (tiered subscription model), The

The Australian government cited national security considerations in refusing to release details of its no-bid, multi-million dollar purchase of an antiviral medicine stockpile for use in case of a flu pandemic. The government decided to purchase Tamiflu, rather than Relenza, which was developed by Biota, a small Melbourne biotech firm. Biota has filed suit against GlaxoSmithKline, alleging the company failed to adequately promote Relenza under a licensing agreement.

View Full Article in:

Australian (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID